The intuition that more screening is better runs deep. If a test can find a disease earlier, surely catching it earlier is good. If we can detect a tumor at a millimeter rather than a centimeter, we’ve won. The slogan “early detection saves lives” has been repeated so often that questioning it feels like questioning medicine itself.
But the evidence for many widely promoted screenings is weaker than the marketing suggests, and the cost of overdiagnosis, in unnecessary surgeries, anxiety, complications, and money, is large enough that it deserves a more honest public conversation.
What overdiagnosis actually means
Overdiagnosis is not misdiagnosis. It’s the correct identification of a condition that, left alone, would never have caused symptoms or death. The patient genuinely has the abnormality. The test isn’t wrong. But the abnormality wasn’t going to harm them, and now they’re a patient.
Thyroid cancer is a textbook example. South Korea’s screening campaign in the 2000s caused thyroid cancer diagnoses to multiply, but mortality didn’t budge. Thousands of people had their thyroids removed for cancers that wouldn’t have killed them. Similar dynamics show up in prostate cancer screening, where PSA tests catch many cancers that grow too slowly to matter, and in some breast cancer screening cohorts where ductal carcinoma in situ may never progress.
The harm isn’t theoretical. Surgery, radiation, and lifelong medication carry real complications. A patient diagnosed with a cancer that would have stayed dormant has been harmed by the diagnosis itself.
Why the system pushes toward more
The financial incentives in healthcare reward finding things. A radiologist who reads more scans, an oncologist who treats more patients, a hospital that performs more procedures all benefit from a system that screens aggressively. Patients also push for testing because the cultural script says responsible adults get screened.
Insurance design reinforces it. Preventive screenings are often covered with no copay, while the downstream costs of false positives and overtreatment fall on patients in deductibles and out-of-pocket spending. The system makes the entry to the funnel cheap and the exit expensive, which guarantees more entries.
Medical guidelines have begun pushing back. The U.S. Preventive Services Task Force has narrowed recommendations for several screenings over the past decade. But guideline changes lag clinical inertia, and patients who’ve been told for years that annual scans save lives don’t easily accept “actually, you don’t need that.”
What the evidence supports
Some screening saves lives. Colon cancer screening with colonoscopy or stool tests has strong evidence of mortality reduction. Cervical cancer screening dramatically reduced deaths. Hypertension and diabetes screening identify treatable conditions cheaply.
Other screenings have a more ambiguous record, and population-level claims about lives saved often don’t survive careful analysis. The right answer is usually screening that’s targeted to actual risk profiles, not blanket recommendations applied to everyone over a given age.
The bottom line
Overdiagnosis is real, and the medical system has been slow to grapple with it. That doesn’t mean you should refuse screening. It means you should ask your doctor whether the specific test, at your specific age and risk profile, has evidence of improving outcomes for people like you. The honest answer is sometimes no.
Leave a Reply